Appropriatezza diagnostico-terapeutica in oncologia - Quaderni del ...

Ministero della Salute
tors predicting outcome. Haematologica 2009; 94:
230-8
Schulz H, Bohlius JF, Trelle S, et al. Imunochemotherapy
with rituximab and overall survival in patients
with indolent or mantle cell lymphoma: a systemic
review and meta-analysis. J Natl Cancer Inst 2007;
99: 706-14
Shouten Qian W, Kvaloy S, Porcellini A, et al. Highdose
therapy improves progression-free survival and
survival in relapsed follicular non-Hodgkin’s lymphoma:
results from the randomized European CUP
trial. J Clin Oncol 2003; 21: 3918-27
Solal-Céligny P, Roy P, Colombat P, et al. Follicular
lymphoma international prognostic index. Blood 2004;
104: 1258-65
Studio GELA, Gisselbrecth C, et al. Blood 2007; 110:
22a
Sweetenham JW. Highly aggressive lymphomas in
adults. Hematol Oncol Clin North Am 2008; 22:
965-78
Swerdlow SH, Campo E, Harris NL, et al. (eds.).
WHO Classification of Tumours of Haematopoietic
and Lymphoid Tissues. 4 th Edition. Lyon: IARC Press,
2008
Tarella C, Zanni M, Di Nicola M, et al., Gruppo Italiano
Terapie Innovative nei Linfomi. Prolonged survival
in poor-risk diffuse large B-cell lymphoma following
front-line treatment with rituximab-supplemented,
early-intensified chemotherapy with multiple autologous
hematopoietic stem cell support: a multicenter
study by GITIL (Gruppo Italiano Terapie Innovative
nei Linfomi). Leukemia 2007; 21: 1802-11
Tubiana M, Henry-Amar M, Carde P, et al. Toward
comprehensive management tailored to prognostic factors
of patients with clinical stages I and II in Hodgkin’s
disease. The EORTC Lymphoma Group controlled
clinical trials. 1964-1987. Blood 1989; 73: 47-56
Van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab
maintenance improves clinical outcome of relapse/resistant
follicular non-Hodgkin lymphoma in patients
both with and without rituximab during induction: results
of a prospective randomized phase 3 intergroup
trial. Blood 2006; 108: 3295-301
Vitolo U, et al. Blood 2008; 112: 834a
Witzig TE, Gordon LI, Cabanillas F, et al. Randomized
controlled trial of yttrium-90-labeled ibritumomab tiuxetan
radioimmunotherapy versus rituximab immunotherapy
for patients with relapsed or refractory lowgrade,
follicular, or transformed B-cell non-Hodgkin’s
lymphoma. J Clin Oncol 2002; 20: 2453-63
Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine
plus mitoxantrone with and without rituximab versus
CHOP with and without rituximab as front-line treatment
for patients with follicular lymphoma. J Clin
Oncol 2004; 22: 2654-61
148